TRANSFUSION-DEPENDENT THALASSEMIA
Clinical trials for TRANSFUSION-DEPENDENT THALASSEMIA explained in plain language.
Never miss a new study
Get alerted when new TRANSFUSION-DEPENDENT THALASSEMIA trials appear
Sign up with your email to follow new studies for TRANSFUSION-DEPENDENT THALASSEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug YOLT-204 aims to reduce transfusions in blood disorders
Disease control Not yet recruitingThis early-phase trial will test a single dose of a new drug called YOLT-204 in 18 children and teens with transfusion-dependent β-thalassemia or sickle cell disease. The goal is to see if it is safe and can raise fetal hemoglobin levels enough to reduce the need for blood transf…
Matched conditions: TRANSFUSION-DEPENDENT THALASSEMIA
Phase: EARLY_PHASE1 • Sponsor: Guangzhou Women and Children's Medical Center • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Talking therapy could help thalassemia patients take their meds
Symptom relief Not yet recruitingThis study tests whether motivational interviewing, a type of counseling, can help adults with beta-thalassemia major follow their iron chelation therapy more consistently. Forty-five participants in Oman will receive three one-on-one sessions with a nurse over six to eight weeks…
Matched conditions: TRANSFUSION-DEPENDENT THALASSEMIA
Phase: NA • Sponsor: Oman Ministry of Health • Aim: Symptom relief
Last updated Jun 27, 2026 14:01 UTC